- Accession Number
- Small Molecule
Polidocanol is a sclerosing agent indicated to treat uncomplicated spider veins (varicose veins ≤1 mm in diameter) and uncomplicated reticular veins (varicose veins 1 to 3 mm in diameter) in the lower extremity. It is marketed under the brand names Asclera and Varithena. The formula for Polidocanol has the structural formula C12H25(OCH2CH2)nOH, a mean extent of polymerization (n) of approximately 9 and a mean molecular weight of approximately 600.
- Laureth 9
- Macrogol 9 lauryl ether
- Nonaethylene glycol monododecyl ether
- Nonaethylene glycol monolauryl ether
- PEG-9 lauryl ether
- Polyethylene glycol 450 lauryl ether
- Polyoxyl 9 lauryl ether
- External IDs
- Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Asclera Injection, solution 0.00500 g/1mL Intravenous Merz North America, Inc 2010-06-01 Not applicable Asclera Injection, solution 0.01000 g/1mL Intravenous Merz North America, Inc 2010-06-01 Not applicable Varithena Kit 180 mg/1mL Intravenous Biocompatibles, Inc. 2013-11-25 Not applicable Varithena Kit 1.3 mg Intravenous Provensis Ltd 2016-11-30 Not applicable Varithena Kit 180 mg/1mL Intravenous Biocompatibles, Inc. 2014-07-10 Not applicable Varithena TM Kit 180 mg/1mL Intravenous Biocompatibles, Inc. 2014-07-10 Not applicable
- International/Other Brands
- Antivaricose Therapy
- Cardiovascular Agents
- Compounds used in a research, industrial, or household setting
- Ethylene Glycols
- Household Products
- Macromolecular Substances
- Pegylated agents
- Pharmaceutical Preparations
- Pharmaceutical Solutions
- Polyethylene Glycols
- Sclerosing Activity
- Sclerosing Agents for Local Injection
- Sclerosing Solutions
- Surface-Active Agents
- Vascular Sclerosing Activity
- CAS number
- Average: 582.8073
- Chemical Formula
- InChI Key
- IUPAC Name
Polidocanol is a sclerosing agent indicated to treat uncomplicated spider veins and uncomplicated reticular veins in the lower extremity.
- Associated Conditions
Polidocanol has a concentration and volume dependent damaging effect on the blood vessel endothelium.
- Mechanism of action
When administered, polidocanol locally damages blood vessel endothelium. Following the endothelial damage, platelets aggregate at the site and attach to the venous wall eventually resulting in a dense network of platelets, cellular debris, and fibrin that occludes the vessel. Eventually the vessel is replaced by connective fibrous tissue.
When given intravenously, the maximum blood concentrations were reached in 15 mins.
- Volume of distribution
When given intravenously, the volume of distribution was 35-82L.
- Protein binding
Plasma protein binding was not measured.
Metabolism was not measured.
- Route of elimination
Route of elimination was not indicated.
- Half life
The half-life is approximately 1.5 h.
Sytemic clearance was 0.2-0.4 L/min.
Most adverse reactions are related to the intravenous administration such as local irritation, pain, and hematoma. Extravasation can also be an issue.
- Affected organisms
- Humans and other mammals
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Comprehensive structured data on known drug adverse effects with statistical prevalence. MedDRA and ICD10 ids are provided for adverse effect conditions and symptoms.Learn more
Structured data covering drug contraindications. Each contraindication describes a scenario in which the drug is not to be used. Includes restrictions on co-administration, contraindicated populations, and more.Learn more
Structured data representing warnings from the black box section of drug labels. These warnings cover important and dangerous risks, contraindications, or adverse effects.Learn more
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Abicipar Pegol The therapeutic efficacy of Abicipar Pegol can be decreased when used in combination with Polidocanol. Antihemophilic Factor (Recombinant), PEGylated The therapeutic efficacy of Antihemophilic Factor (Recombinant), PEGylated can be decreased when used in combination with Polidocanol. Cepeginterferon alfa-2B The therapeutic efficacy of Cepeginterferon alfa-2B can be decreased when used in combination with Polidocanol. Certolizumab pegol The therapeutic efficacy of Certolizumab pegol can be decreased when used in combination with Polidocanol. Damoctocog alfa pegol The therapeutic efficacy of Damoctocog alfa pegol can be decreased when used in combination with Polidocanol. Egaptivon pegol The therapeutic efficacy of Polidocanol can be decreased when used in combination with Egaptivon pegol. Elapegademase The therapeutic efficacy of Elapegademase can be decreased when used in combination with Polidocanol. Eptacog alfa pegol (activated) The therapeutic efficacy of Eptacog alfa pegol (activated) can be decreased when used in combination with Polidocanol. GlycoPEG-GCSF The therapeutic efficacy of Polidocanol can be decreased when used in combination with GlycoPEG-GCSF. Heptaethylene glycol The therapeutic efficacy of Polidocanol can be decreased when used in combination with Heptaethylene glycol.Additional Data Available
- Extended DescriptionExtended Description
Extended description of the mechanism of action and particular properties of each drug interaction.Learn more
A severity rating for each drug interaction, from minor to major.Learn more
- Evidence LevelEvidence Level
A rating for the strength of the evidence supporting each drug interaction.Learn more
An effect category for each drug interaction. Know how this interaction affects the subject drug.Learn more
- Food Interactions
- No interactions found.
- General References
- Peterson JD, Goldman MP, Weiss RA, Duffy DM, Fabi SG, Weiss MA, Guiha I: Treatment of reticular and telangiectatic leg veins: double-blind, prospective comparative trial of polidocanol and hypertonic saline. Dermatol Surg. 2012 Aug;38(8):1322-30. doi: 10.1111/j.1524-4725.2012.02422.x. Epub 2012 May 23. [PubMed:22620717]
- Weiss RA, Voigts R, Howell DJ: Absence of concentration congruity in six compounded polidocanol samples obtained for leg sclerotherapy. Dermatol Surg. 2011 Jun;37(6):812-5. doi: 10.1111/j.1524-4725.2011.01906..x. [PubMed:21605244]
- Link [Link]
- External Links
- ATC Codes
- C05BB02 — Polidocanol
- AHFS Codes
- 24:16.00 — Sclerosing Agents
- PDB Entries
- 3dm8 / 5k9d
- FDA label
- Download (86.7 KB)
- Download (567 KB)
- Clinical Trials
- Not Available
- Not Available
- Dosage forms
Form Route Strength Injection, solution Intravenous 0.00500 g/1mL Injection, solution Intravenous 0.01000 g/1mL Kit Intravenous 1.3 mg Kit Intravenous 180 mg/1mL
- Not Available
Patent Number Pediatric Extension Approved Expires (estimated) US7814943 No 2010-10-19 2027-11-19 US7842282 No 2010-11-30 2020-05-26 US7604185 No 2009-10-20 2020-05-26 US7357336 No 2008-04-15 2020-05-26 US7025290 No 2006-04-11 2020-05-26 US6572873 No 2003-06-03 2020-05-26 US7731986 No 2010-06-08 2024-11-17 USRE40640 No 2009-02-17 2016-10-14 US8734833 No 2014-05-27 2020-05-26 US8122917 No 2012-02-28 2024-09-09 US6942165 No 2005-09-13 2020-05-26 US8323677 No 2012-12-04 2020-05-26 US6846412 No 2005-01-25 2022-07-19 US7842283 No 2010-11-30 2020-05-26 US9480652 No 2016-11-01 2032-05-12Additional Data Available
- Filed OnFiled On
The date on which a patent was filed with the relevant government.Learn more
- Experimental Properties
Property Value Source melting point (°C) 33-36 °C Not Available boiling point (°C) 615.857 °C at 760 mmHg Not Available water solubility miscible http://ec.europa.eu/health/ph_risk/committees/04_sccp/docs/sccp_o_113.pdf logP 3.94 # http://www.chemicalize.org/structure/#!mol=polidocanol
- Predicted Properties
Property Value Source Water Solubility 0.000403 mg/mL ALOGPS logP 3.15 ALOGPS logP 3.94 ChemAxon logS -6.2 ALOGPS pKa (Strongest Acidic) 15.12 ChemAxon pKa (Strongest Basic) -2.7 ChemAxon Physiological Charge 0 ChemAxon Hydrogen Acceptor Count 10 ChemAxon Hydrogen Donor Count 1 ChemAxon Polar Surface Area 103.3 Å2 ChemAxon Rotatable Bond Count 37 ChemAxon Refractivity 158.33 m3·mol-1 ChemAxon Polarizability 74.51 Å3 ChemAxon Number of Rings 0 ChemAxon Bioavailability 0 ChemAxon Rule of Five No ChemAxon Ghose Filter No ChemAxon Veber's Rule No ChemAxon MDDR-like Rule No ChemAxon
- Predicted ADMET features
- Not Available
- Mass Spec (NIST)
- Download (10.2 KB)
Spectrum Spectrum Type Splash Key Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available
- This compound belongs to the class of organic compounds known as polyethylene glycols. These are oligomers or polymers of ethylene oxide, with the general formula (C2H4O)n (with n>=3).
- Organic compounds
- Super Class
- Organic oxygen compounds
- Organooxygen compounds
- Sub Class
- Direct Parent
- Polyethylene glycols
- Alternative Parents
- Primary alcohols / Hydrocarbon derivatives
- Polyethylene glycol / Hydrocarbon derivative / Primary alcohol / Alcohol / Aliphatic acyclic compound
- Molecular Framework
- Aliphatic acyclic compounds
- External Descriptors
- hydroxypolyether (CHEBI:46859)
Drug created on September 14, 2010 10:21 / Updated on February 25, 2020 00:17